DBV Technologies Delays VIASKIN Peanut Patch BLA Submission to Q3 2026 for FDA Feedback Integration
DBVT sits 88% above its 52-week low of $8.51 on elevated volume (2.0× avg).
Summary
DBV Technologies announced a delay in its Biologics License Application (BLA) submission for the VIASKIN Peanut Patch to Q3 2026, citing the need to incorporate FDA feedback for an optimized review process.
Key Events · Product Development and Regulatory · DBVT
-
BLA Submission Delayed
DBV Technologies now anticipates submitting the Biologics License Application (BLA) for its VIASKIN Peanut Patch in children aged 4 through 7 years in the third quarter of 2026.
-
Reason for Delay
The delay is to incorporate valuable, actionable input from the FDA regarding the organization, mapping, and formatting of existing data sets for the CMC and biostatistical elements of the BLA.
-
No Additional Data Requested
The FDA has not requested any additional data, indicating the delay is procedural for optimization rather than a clinical setback.
-
Conference Call Scheduled
DBV management will host an investor conference call and webcast today, June 29, 2026, at 5:00 PM ET to discuss this update.
Analysis · DBVT · Life Sciences
This filing announces a delay in the Biologics License Application (BLA) submission for DBV's key product, the VIASKIN Peanut Patch, pushing the anticipated filing to Q3 2026. While the company emphasizes collaborative engagement with the FDA and states no additional data was requested, any delay in a regulatory submission for a late-stage product can impact the timeline for potential market entry and revenue generation. Investors will be watching for the actual submission in Q3 and subsequent FDA review progress.
At the time of this filing, DBVT was trading at $16.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $968.5M. The 52-week trading range was $8.51 to $26.19. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.